Abstract 702P
Background
Human leukocyte antigens (HLAs) are expressed in a variety of cells, including cancer cells and immune cells. Recent studies have shown that germline HLA gene zygosity, supertype and individual HLA genotypes may be associated with immunotherapy (IO) outcomes. We aimed to evaluate whether germline HLA-A gene haplotype and zygosity is associated with response to IO.
Methods
Pts enrolled in phase 1 clinical trials in the Vall d´Hebron Institute of Oncology Early Drug Development Unit with available HLA-A testing were reviewed. Median progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results
From 2021 to 2023 a total of 247 eligible pts were reviewed. Median age was 59y, 63% female, main types of tumor with positive HLA biomarker were colorectal/anal cancer 19% (47pts), gynecological tumors 14%(34pts); and breast cancer 14% (34pts). Alleles present at >5% samples: 02:01:01 25%, 01:01:01 11%, 03:01:01 11%, 24:02:01 9%, 29:02:01 8%. Twenty-five (10.20%) pts presented HLA-A homozygosis. Homozygosis occurred in the most common haplotypes: 02:01:01 (14pts), 01:01:01 (2pts), 03:01:01 (4pts%), 24:02:01 (2pts%) and 29:02:01 (2pts). Eighty-five (34.5%) pts received IO; main types of tumors that received IO were genitourinary tumors 67% (10pts), gynecological tumors 45% (16pts) and colorectal/anal tumors 27% (13pts). Pts treated with anti-PD1 were 17 (20%), anti-PDL1 17 (20%) and other combinations 20 (24%). Twelve patients (17%) had PR, and thirty eight (45%) SD. Overal PFS and OS was 6.1 months and 29.6 months respectively. Presence of 03:01:01 was associated with a higher likelihood of response. Six pts with HLA homozygosis received inmunotherapy, all of them achieved SD as best response (NS).
Conclusions
Prevalence of HLA 02:01:01 in our population is significantly lower than reported in other populations. Presence of Homozygoses was not significantly associated with lack of response to inmunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa, by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17